menu
    • menu
    [{"orgOrder":0,"company":"Neogene","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Neo-Antigen T Cell Receptor","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Neogene","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"Neogene \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Neogene \/ EcoR1 Capital"},{"orgOrder":0,"company":"Neogene","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"CAR-T cell therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Neogene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Neogene \/ Neogene","highestDevelopmentStatusID":"2","companyTruncated":"Neogene \/ Neogene"},{"orgOrder":0,"company":"Neogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"NT-125","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neogene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Neogene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neogene \/ Not Applicable"},{"orgOrder":0,"company":"Neogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"TCR Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Neogene","amount2":0.32000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Neogene \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Neogene \/ AstraZeneca"},{"orgOrder":0,"company":"Neogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"TCR-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Neogene","amount2":0.32000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Neogene \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Neogene \/ AstraZeneca"}]

    Find Clinical Drug Pipeline Developments & Deals by Neogene

    Menu

    Neogene

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neogene

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Neogene

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCR Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : AstraZeneca

                            Deal Size : $320.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AstraZeneca To Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy

                            Details : With a shared goal of bringing cell therapies to patients with solid tumours, Neogene’s expertise in TCR-T discovery, development and manufacturing will strengthen AstraZeneca’s ambition to transform outcomes for patients.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $200.0 million

                            November 29, 2022

                            Lead Product(s) : TCR Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : AstraZeneca

                            Deal Size : $320.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neogene

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Neogene

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NT-125

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fu...

                            Details : NT-125, designed to contain up to five distinct neoantigen-specific TCRs per patient in single cell product of highly functional engineered T cells, allowing multiple neoantigens by HLA molecules targeted with goal to create a more impactful TCR therapy ...

                            Brand Name : NT-125

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 10, 2022

                            Lead Product(s) : NT-125

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neogene

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Neogene

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCR-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : AstraZeneca

                            Deal Size : $320.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Acquisition of Neogene Therapeutics Completed

                            Details : Acquisition will provide access to next-generation T-cell receptor therapies with promising potential for targeting solid tumours to AstraZeneca. TCR-based Therapies can recognise intracellular targets, including cancer-specific mutations.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $320.0 million

                            January 16, 2022

                            Lead Product(s) : TCR-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : AstraZeneca

                            Deal Size : $320.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Neogene

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Neogene

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-T cell therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Twist Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Ther...

                            Details : The companies will leverage Neogene’s expertise in targeting tumor neo-antigens, mutated proteins found in cancer cells together with Twist’s DNA synthesis platform and product lines to develop personalized CAR) T cell therapies and TCR therapies for...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 13, 2020

                            Lead Product(s) : CAR-T cell therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Twist Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Neogene

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Neogene

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neo-Antigen T Cell Receptor

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : EcoR1 Capital

                            Deal Size : $110.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Neo-Antigen TCR Therapi...

                            Details : Neogene’s proprietary technology platform identifies specific T cell receptor (TCR) genes from routine tumor samples using state-of-the-art synthetic biology tools.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 14, 2020

                            Lead Product(s) : Neo-Antigen T Cell Receptor

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : EcoR1 Capital

                            Deal Size : $110.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth